Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Procedural Anxiety, Pain Catastrophizing, and Procedure-Related Pain during EGD and Colonoscopy.

Lauriola M, Tomai M, Palma R, La Spina G, Foglia A, Panetta C, Raniolo M, Pontone S.

South Med J. 2020 Jan;113(1):8-15. doi: 10.14423/SMJ.0000000000001058.

PMID:
31897492
2.

Coated microneedles for transdermal delivery of a potent pharmaceutical peptide.

Kapoor Y, Milewski M, Dick L, Zhang J, Bothe JR, Gehrt M, Manser K, Nissley B, Petrescu I, Johnson P, Burton S, Moseman J, Hua V, Grunewald T, Tomai M, Smith R.

Biomed Microdevices. 2019 Dec 16;22(1):7. doi: 10.1007/s10544-019-0462-1.

PMID:
31845070
3.

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation.

Saunders KO, Wiehe K, Tian M, Acharya P, Bradley T, Alam SM, Go EP, Scearce R, Sutherland L, Henderson R, Hsu AL, Borgnia MJ, Chen H, Lu X, Wu NR, Watts B, Jiang C, Easterhoff D, Cheng HL, McGovern K, Waddicor P, Chapdelaine-Williams A, Eaton A, Zhang J, Rountree W, Verkoczy L, Tomai M, Lewis MG, Desaire HR, Edwards RJ, Cain DW, Bonsignori M, Montefiori D, Alt FW, Haynes BF.

Science. 2019 Dec 6;366(6470). pii: eaay7199. doi: 10.1126/science.aay7199. No abstract available.

PMID:
31806786
4.

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.

Mullins SR, Vasilakos JP, Deschler K, Grigsby I, Gillis P, John J, Elder MJ, Swales J, Timosenko E, Cooper Z, Dovedi SJ, Leishman AJ, Luheshi N, Elvecrog J, Tilahun A, Goodwin R, Herbst R, Tomai MA, Wilkinson RW.

J Immunother Cancer. 2019 Sep 11;7(1):244. doi: 10.1186/s40425-019-0724-8.

5.

Intolerance of Uncertainty and Anxiety-Related Dispositions Predict Pain During Upper Endoscopy.

Lauriola M, Tomai M, Palma R, La Spina G, Foglia A, Panetta C, Raniolo M, Pontone S.

Front Psychol. 2019 May 15;10:1112. doi: 10.3389/fpsyg.2019.01112. eCollection 2019.

6.

Biopsychosocial Correlates of Adjustment to Cancer during Chemotherapy: The Key Role of Health-Related Quality of Life.

Lauriola M, Tomai M.

ScientificWorldJournal. 2019 Mar 10;2019:9750940. doi: 10.1155/2019/9750940. eCollection 2019.

7.

Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques.

Petitdemange C, Kasturi SP, Kozlowski PA, Nabi R, Quarnstrom CF, Reddy PBJ, Derdeyn CA, Spicer LM, Patel P, Legere T, Kovalenkov YO, Labranche CC, Villinger F, Tomai M, Vasilakos J, Haynes B, Kang CY, Gibbs JS, Yewdell JW, Barouch D, Wrammert J, Montefiori D, Hunter E, Amara RR, Masopust D, Pulendran B.

JCI Insight. 2019 Feb 21;4(4). pii: 126047. doi: 10.1172/jci.insight.126047. eCollection 2019 Feb 21.

8.

Psychological, emotional and social impairments are associated with adherence and healthcare spending in type 2 diabetic patients: an observational study.

Lai C, Filippetti G, Schifano I, Aceto P, Tomai M, Lai S, Pierro L, Renzi A, Carnovale A, Maranghi M.

Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):749-754. doi: 10.26355/eurrev_201901_16889.

9.

Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques.

Phillips B, Van Rompay KKA, Rodriguez-Nieves J, Lorin C, Koutsoukos M, Tomai M, Fox CB, Eudailey J, Dennis M, Alam SM, Hudgens M, Fouda G, Pollara J, Moody A, Shen X, Ferrari G, Permar S, De Paris K.

J Virol. 2018 Sep 26;92(20). pii: e01051-18. doi: 10.1128/JVI.01051-18. Print 2018 Oct 15.

10.

Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica.

Abhyankar MM, Orr MT, Lin S, Suraju MO, Simpson A, Blust M, Pham T, Guderian JA, Tomai MA, Elvecrog J, Pedersen K, Petri WA Jr, Fox CB.

NPJ Vaccines. 2018 Jun 5;3:22. doi: 10.1038/s41541-018-0060-x. eCollection 2018.

11.

The Impact Of Dispositional Variables Of Elders, Relatives, And Paid Caregivers On Elders' Empowerment And Life Satisfaction.

Tomai M, Pezzuti L, Mebane M, Benedetti M, Moro A.

Exp Aging Res. 2017 Jul-Sep;43(4):367-378. doi: 10.1080/0361073X.2017.1333833.

PMID:
28718757
12.

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.

Van Hoeven N, Fox CB, Granger B, Evers T, Joshi SW, Nana GI, Evans SC, Lin S, Liang H, Liang L, Nakajima R, Felgner PL, Bowen RA, Marlenee N, Hartwig A, Baldwin SL, Coler RN, Tomai M, Elvecrog J, Reed SG, Carter D.

Sci Rep. 2017 Apr 21;7:46426. doi: 10.1038/srep46426.

13.

TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth.

Dowling DJ, van Haren SD, Scheid A, Bergelson I, Kim D, Mancuso CJ, Foppen W, Ozonoff A, Fresh L, Theriot TB, Lackner AA, Fichorova RN, Smirnov D, Vasilakos JP, Beaurline JM, Tomai MA, Midkiff CC, Alvarez X, Blanchard JL, Gilbert MH, Aye PP, Levy O.

JCI Insight. 2017 Mar 23;2(6):e91020. doi: 10.1172/jci.insight.91020.

14.

Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.

Abhyankar MM, Noor Z, Tomai MA, Elvecrog J, Fox CB, Petri WA Jr.

Vaccine. 2017 Feb 7;35(6):916-922. doi: 10.1016/j.vaccine.2016.12.057. Epub 2017 Jan 12.

15.

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.

Fox CB, Orr MT, Van Hoeven N, Parker SC, Mikasa TJ, Phan T, Beebe EA, Nana GI, Joshi SW, Tomai MA, Elvecrog J, Fouts TR, Reed SG.

J Control Release. 2016 Dec 28;244(Pt A):98-107. doi: 10.1016/j.jconrel.2016.11.011. Epub 2016 Nov 12.

16.

Dispositional characteristics, relational well-being and perceived life satisfaction and empowerment of elders.

Francescato D, Pezzuti L, Mebane M, Tomai M, Benedetti M, Moro A.

Aging Ment Health. 2017 Oct;21(10):1052-1057. doi: 10.1080/13607863.2016.1191058. Epub 2016 Jun 1.

PMID:
27248667
17.

Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.

Schölch S, Rauber C, Tietz A, Rahbari NN, Bork U, Schmidt T, Kahlert C, Haberkorn U, Tomai MA, Lipson KE, Carretero R, Weitz J, Koch M, Huber PE.

Oncotarget. 2015 Mar 10;6(7):4663-76.

18.

Effects of 3D microwell culture on initial fate specification in human embryonic stem cells.

Hsiao C, Tomai M, Glynn J, Palecek SP.

AIChE J. 2014 Apr;60(4):1225-1235.

19.

Authors' response.

Welsh L, Nesci C, Tran H, Tomai M, Ranganathan S.

J Cyst Fibros. 2015 Mar;14(2):287. doi: 10.1016/j.jcf.2014.09.004. Epub 2014 Sep 30. No abstract available.

20.

Lung clearance index during hospital admission in school-age children with cystic fibrosis.

Welsh L, Nesci C, Tran H, Tomai M, Ranganathan S.

J Cyst Fibros. 2014 Dec;13(6):687-91. doi: 10.1016/j.jcf.2014.05.012. Epub 2014 Jun 7.

21.

The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.

Vasilakos JP, Tomai MA.

Expert Rev Vaccines. 2013 Jul;12(7):809-19. doi: 10.1586/14760584.2013.811208. Review.

PMID:
23885825
22.

Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways.

Philbin VJ, Dowling DJ, Gallington LC, Cortés G, Tan Z, Suter EE, Chi KW, Shuckett A, Stoler-Barak L, Tomai M, Miller RL, Mansfield K, Levy O.

J Allergy Clin Immunol. 2012 Jul;130(1):195-204.e9. doi: 10.1016/j.jaci.2012.02.042. Epub 2012 Apr 21.

23.

Is alexithymia related to colon cancer? A survey of patients undergoing a screening colonoscopy examination.

Lauriola M, Panno A, Tomai M, Ricciardi V, Potenza AE.

J Clin Psychol Med Settings. 2011 Dec;18(4):410-5. doi: 10.1007/s10880-011-9267-y.

PMID:
21948154
24.

TLR-7 and -8 agonists as vaccine adjuvants.

Tomai MA, Vasilakos JP.

Expert Rev Vaccines. 2011 Apr;10(4):405-7. doi: 10.1586/erv.11.26. No abstract available.

PMID:
21506636
25.

Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide.

Dumitru CD, Antonysamy MA, Tomai MA, Lipson KE.

Cancer Biol Ther. 2010 Jul 15;10(2):155-65. Epub 2010 Jul 26.

PMID:
20519933
26.

NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.

Dumitru CD, Antonysamy MA, Gorski KS, Johnson DD, Reddy LG, Lutterman JL, Piri MM, Proksch J, McGurran SM, Egging EA, Cochran FR, Lipson KE, Tomai MA, Gullikson GW.

Cancer Immunol Immunother. 2009 Apr;58(4):575-87. doi: 10.1007/s00262-008-0581-7. Epub 2008 Sep 13.

PMID:
18791716
27.

TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.

Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP.

J Interferon Cytokine Res. 2008 Apr;28(4):253-63. doi: 10.1089/jir.2007.0097.

PMID:
18439103
28.

The antiviral activity of Toll-like receptor 7 and 7/8 agonists.

Miller RL, Meng TC, Tomai MA.

Drug News Perspect. 2008 Mar;21(2):69-87. Review.

PMID:
18389099
29.

Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands.

Martinson JA, Roman-Gonzalez A, Tenorio AR, Montoya CJ, Gichinga CN, Rugeles MT, Tomai M, Krieg AM, Ghanekar S, Baum LL, Landay AL.

Cell Immunol. 2007 Nov-Dec;250(1-2):75-84. doi: 10.1016/j.cellimm.2008.01.007. Epub 2008 Mar 10.

30.

Resiquimod and other immune response modifiers as vaccine adjuvants.

Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP.

Expert Rev Vaccines. 2007 Oct;6(5):835-47. Review.

PMID:
17931162
31.

Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells.

Severa M, Remoli ME, Giacomini E, Annibali V, Gafa V, Lande R, Tomai M, Salvetti M, Coccia EM.

J Immunol. 2007 May 15;178(10):6208-16.

32.

Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.

Hammerbeck DM, Burleson GR, Schuller CJ, Vasilakos JP, Tomai M, Egging E, Cochran FR, Woulfe S, Miller RL.

Antiviral Res. 2007 Jan;73(1):1-11. Epub 2006 Aug 18.

PMID:
16959331
33.

Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.

Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, Gorden KB, Miller JS, Vasilakos JP, Tomai MA, Alkan SS.

Int Immunol. 2006 Jul;18(7):1115-26. Epub 2006 May 25.

PMID:
16728430
34.

Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.

Thatcher TH, Luzina I, Fishelevich R, Tomai MA, Miller RL, Gaspari AA.

J Invest Dermatol. 2006 Apr;126(4):821-31.

35.

Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells.

Spaner DE, Shi Y, White D, Mena J, Hammond C, Tomic J, He L, Tomai MA, Miller RL, Booth J, Radvanyi L.

Leukemia. 2006 Feb;20(2):286-95.

PMID:
16341037
36.

Imiquimod 5% cream (Aldara).

Slade HB, Owens ML, Tomai MA, Miller RL.

Expert Opin Investig Drugs. 1998 Mar;7(3):437-49.

PMID:
15991984
37.

Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production.

Gerster JF, Lindstrom KJ, Miller RL, Tomai MA, Birmachu W, Bomersine SN, Gibson SJ, Imbertson LM, Jacobson JR, Knafla RT, Maye PV, Nikolaides N, Oneyemi FY, Parkhurst GJ, Pecore SE, Reiter MJ, Scribner LS, Testerman TL, Thompson NJ, Wagner TL, Weeks CE, Andre JD, Lagain D, Bastard Y, Lupu M.

J Med Chem. 2005 May 19;48(10):3481-91.

PMID:
15887957
38.

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP.

J Immunol. 2005 Feb 1;174(3):1259-68.

39.

Topically applied imiquimod inhibits vascular tumor growth in vivo.

Sidbury R, Neuschler N, Neuschler E, Sun P, Wang XQ, Miller R, Tomai M, Puscasiu E, Gugneja S, Paller AS.

J Invest Dermatol. 2003 Nov;121(5):1205-9.

40.

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.

Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, Noelle RJ, Miller RL, Kedl RM, Fitzgerald-Bocarsly P, Tomai MA, Vasilakos JP.

Cell Immunol. 2002 Jul-Aug;218(1-2):74-86.

PMID:
12470615
41.

Immunomodulation as a treatment strategy for genital herpes: review of the evidence.

Miller RL, Tomai MA, Harrison CJ, Bernstein DI.

Int Immunopharmacol. 2002 Mar;2(4):443-51. Review.

PMID:
11962724
42.

The immune response modifier resiquimod mimics CD40-induced B cell activation.

Bishop GA, Ramirez LM, Baccam M, Busch LK, Pederson LK, Tomai MA.

Cell Immunol. 2001 Feb 25;208(1):9-17.

PMID:
11277614
43.

Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment.

Bernstein DI, Harrison CJ, Tomai MA, Miller RL.

J Infect Dis. 2001 Mar 15;183(6):844-9. Epub 2001 Feb 13.

PMID:
11237799
44.

Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848.

Bishop GA, Hsing Y, Hostager BS, Jalukar SV, Ramirez LM, Tomai MA.

J Immunol. 2000 Nov 15;165(10):5552-7.

45.

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.

Vasilakos JP, Smith RM, Gibson SJ, Lindh JM, Pederson LK, Reiter MJ, Smith MH, Tomai MA.

Cell Immunol. 2000 Aug 25;204(1):64-74.

PMID:
11006019
46.

The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes.

Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ.

Cell Immunol. 2000 Jul 10;203(1):55-65.

PMID:
10915562
47.

Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts.

Arany I, Tyring SK, Brysk MM, Stanley MA, Tomai MA, Miller RL, Smith MH, McDermott DJ, Slade HB.

Antimicrob Agents Chemother. 2000 Jul;44(7):1869-73.

48.

Mechanism of action of imiquimod 5% cream in the treatment of anogenital warts.

Tyring SK, Arany I I, Stanley MA, Stoler MH, Tomai MA, Miller RL, Owens ML, Smith MH.

Prim Care Update Ob Gyns. 1998 Jul 1;5(4):151-152.

PMID:
10838280
49.

Effect of imiquimod on cytokine induction in first trimester trophoblasts.

Manlove-Simmons JM, Zaher FM, Tomai M, Gonik B, Svinarich DM.

Infect Dis Obstet Gynecol. 2000;8(2):105-11.

50.

Imiquimod, a topical immune response modifier, induces migration of Langerhans cells.

Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, Miller RL, Sauder DN.

J Invest Dermatol. 2000 Jan;114(1):135-41.

Supplemental Content

Support Center